A. Guerci

2.9k total citations
26 papers, 1.3k citations indexed

About

A. Guerci is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, A. Guerci has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 12 papers in Molecular Biology and 9 papers in Genetics. Recurrent topics in A. Guerci's work include Acute Myeloid Leukemia Research (17 papers), Retinoids in leukemia and cellular processes (10 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). A. Guerci is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Retinoids in leukemia and cellular processes (10 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). A. Guerci collaborates with scholars based in France, Belgium and Switzerland. A. Guerci's co-authors include Pierre Fenaux, Sylvie Castaigné, E Archimbaud, M Duarte, Christine Chomienne, M. Le Deley, Deborah A. Bowen, MT Daniel, Hartmut Link and Hervé Dombret and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

A. Guerci

24 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Guerci France 13 1.1k 896 266 215 194 26 1.3k
José D. González Spain 11 1.4k 1.3× 1.3k 1.5× 280 1.1× 366 1.7× 78 0.4× 18 1.6k
Chelo Rayón Spain 7 758 0.7× 748 0.8× 163 0.6× 222 1.0× 51 0.3× 15 871
Vivi M. Srivastava India 12 442 0.4× 424 0.5× 127 0.5× 105 0.5× 113 0.6× 29 668
RM Stone United States 9 570 0.5× 282 0.3× 469 1.8× 22 0.1× 123 0.6× 13 940
Christine von Neuhoff Germany 16 736 0.7× 302 0.3× 422 1.6× 9 0.0× 99 0.5× 24 889
Wenyuan Mai China 13 326 0.3× 199 0.2× 66 0.2× 65 0.3× 50 0.3× 44 442
J O Moore United States 9 436 0.4× 148 0.2× 169 0.6× 18 0.1× 126 0.6× 9 600
Jan Maxwell Nørgaard Denmark 17 724 0.7× 340 0.4× 298 1.1× 8 0.0× 229 1.2× 48 922
Elvira Deolinda Rodrigues Pereira Velloso Brazil 13 423 0.4× 184 0.2× 117 0.4× 15 0.1× 209 1.1× 81 654
Amrana Qureshi United Kingdom 10 379 0.4× 91 0.1× 65 0.2× 12 0.1× 217 1.1× 18 653

Countries citing papers authored by A. Guerci

Since Specialization
Citations

This map shows the geographic impact of A. Guerci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Guerci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Guerci more than expected).

Fields of papers citing papers by A. Guerci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Guerci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Guerci. The network helps show where A. Guerci may publish in the future.

Co-authorship network of co-authors of A. Guerci

This figure shows the co-authorship network connecting the top 25 collaborators of A. Guerci. A scholar is included among the top collaborators of A. Guerci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Guerci. A. Guerci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tessoulin, Benoît, A. Guerci, Emmanuel Gyan, et al.. (2013). P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study. Leukemia Research. 37. S161–S161. 2 indexed citations
2.
Park, Sophie, Rosa Sapena, Charikleia Kelaïdi, et al.. (2011). Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. Leukemia Research. 35(11). 1530–1533. 16 indexed citations
3.
Kelaïdi, Charikleia, Aspasia Stamatoullas, Odile Beyne‐Rauzy, et al.. (2009). Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica. 95(6). 892–899. 13 indexed citations
4.
Tamburini, Jérôme, C. Elie, D. Vassilief, et al.. (2006). Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.. Blood. 108(11). 2673–2673. 1 indexed citations
5.
Callens, Céline, Sylvie Chevret, JM Cayuela, et al.. (2005). Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 19(7). 1153–1160. 91 indexed citations
6.
Thomas, X., Q.H. Le, Stéphane de Botton, et al.. (2005). Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy. Leukemia & lymphoma. 46(7). 1007–1016. 4 indexed citations
7.
Maalouf, T., et al.. (2004). Œdème palpébral secondaire au traitement par inhibiteur de la tyrosine kinase : Glivec®. Journal Français d Ophtalmologie. 27(1). 107–109. 7 indexed citations
8.
Bouscary, Didier, D. Vassilief, Achille Aouba, et al.. (2004). Thalidomide for the Treatment of Low Risk Myelodysplasia.. Blood. 104(11). 1438–1438. 3 indexed citations
9.
Ribrag, Vincent, Florence Suzan, Christophe Ravoet, et al.. (2003). Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Leukemia. 17(2). 319–322. 5 indexed citations
10.
Wattel, Eric, Éric Solary, Xavier Leleu, et al.. (1999). A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia. 13(4). 524–529. 44 indexed citations
11.
Fontenay, Michaëla, et al.. (1997). 95 Serum levels of thrombopoietin (TPO) In myelodysplasias. Leukemia Research. 21(1). S25–S25. 1 indexed citations
12.
Guerci, A., P Lederlin, Dominique Bordessoule, et al.. (1996). Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Annals of Oncology. 7(9). 966–969. 25 indexed citations
13.
Guillemin, François, et al.. (1995). Development of a criterion for response to therapy at 6 months in multiple myeloma. European Journal Of Haematology. 55(2). 110–116. 2 indexed citations
14.
15.
Wattel, Eric, A. Guerci, B Hecquet, et al.. (1994). A randomized trial of hydroxyuea (HY) versus VP16 in advanced adult chronic myelomonocytic leukemia. Leukemia Research. 18. 21–21. 1 indexed citations
16.
17.
Fenaux, Pierre, M. Le Deley, Sylvie Castaigné, et al.. (1993). Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 82(11). 3241–3249. 16 indexed citations
18.
Fenaux, Pierre, M. Le Deley, Sylvie Castaigné, et al.. (1993). Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 82(11). 3241–3249. 373 indexed citations
19.
20.
Scheidt, S, et al.. (1990). Thrombolytic therapy: medical panel discussion. 11(1). 35–55. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José D. González Breakdown of academic impact, for papers by Chelo Rayón Breakdown of academic impact, for papers by Vivi M. Srivastava Breakdown of academic impact, for papers by RM Stone Breakdown of academic impact, for papers by Christine von Neuhoff Breakdown of academic impact, for papers by Wenyuan Mai Breakdown of academic impact, for papers by J O Moore Breakdown of academic impact, for papers by Jan Maxwell Nørgaard Breakdown of academic impact, for papers by Elvira Deolinda Rodrigues Pereira Velloso Breakdown of academic impact, for papers by Amrana Qureshi
Rankless by CCL
2026